June 2009
Sanaria featured in Associated Press article, Pulling malaria from mosquitoes to fight disease
April 2009
Sanaria and PATH-MVI announce that Phase 1 trial of Sanaria's whole-parasite malaria vaccine called PfSPZ Vaccine to begin; FDA approval for testing in humans watershed moment for unique malaria vaccine approach; Press Release
April 2009
Sanaria wins Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech at the World Vaccine Congress Washington. Other awardees include GlaxoSmithKline Biologicals and PATH Malaria Vaccine Initiative for Best Vaccine Partnership/Alliance, GlaxoSmithKline Biologicals for Best Vaccine R&D Pipeline, and Merck for Best Prophylactic Vaccine; ViE; Press Release
December 2008
Sanaria and Sanaria's CEO, Dr. Stephen L. Hoffman, featured in Esquire magazine, The Persistent Primitive Dream of an Implacable Scientist and His Army of Mosquitoes
October 2008
Sanaria and TI Pharma collaborators at Radboud University Nijmegen Medical Centre and Leiden University Medical Centre publish the first report of genetically attenuated P. falciparum sporozoites. Developmentally arrested at an early stage following liver cell invasion, these mutant parasites complement radiation attenuated sporozoite approaches to conferring protective immunity in humans; PLoS ONE; Press Release
July 2008
Sanaria and the University of Maryland Biotechnology Institute awarded collaborative, multi-year, US $600,000 NIH SBIR grant; Press Release
May 2008
Sanaria named Emerging Company of the Year at the annual Technology Council of Maryland's Tech Awards Celebration; Tech Council of Maryland;
Press Release; Gazette.net
March 2008
Sanaria featured in Scientific American; Scientific American
January 2008
Sanaria enters into $23.6 million research agreement; Press Release